Jpmorgan Chase & CO X4 Pharmaceuticals, Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 459,653 shares of XFOR stock, worth $220,633. This represents 0.0% of its overall portfolio holdings.
Number of Shares
459,653
Previous 76,476
501.04%
Holding current value
$220,633
Previous $51,000
592.16%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding XFOR
# of Institutions
97Shares Held
99.6MCall Options Held
421KPut Options Held
80.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$8.12 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$7.19 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$5.12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$3.94 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$3.51 Million2.9% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $33M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...